1/76
Looks like no tags are added yet.
two groups of corticosteroids
glucocorticoids
mineralocorticoids
synthetic glucocorticoids
dexamethasone
betamethasone
triamcinolone
methylprednisolone
hydrocortisone (cortisol)
cortisone
budesonide
beclomethasone
fludrocortisone
natural glucocorticoids - hippocampus pathway
hippocampus triggers hypothalamus to release CRH → pituitary release ACTH → release cortisol from adrenal
clinical uses of synthetic GCs
adrenal insufficiencies
inflammatory conditions
autoimmune diseases
allergic conditions
chronic respiratory illness
infectious diseases
blood malignancies
severe injury
organ transplantation
properties of GCs
inhibitory effects on inflammatory cytokines (interleukins IL-1,2,6) and TNFa
inhibits leukocyte recruitment and immune response
block inflammatory arachidonic acid pathway
GC genomic vs non genomic actions
genomic: GC → GR through transcription→ pharmacological action
non-genomic: → stress kinases through signal transduction → pharmacological action
GC mediated effects are through their receptors belonging to
nuclear receptor family
GR alpha is the active form with 777 aa at C-term
GR B is truncated dominant negative mutant isoform, lacks 35 aa in C-term which lacks normal transcription fx
GR, MR, PR, AR, ER has what dimerization property
homodimerism
TR has what dimerization property
heterodimerization
GC MOI
glucocorticoid diffusion through simple diffusion
bind to GR receptor and GR forms homodimer
chaperone protein release GR homodimer from cytosol to enter nucleus to enhance or repress gene transcription
what is the chaperone in the GC action
Hsp70/90 (heat shock protein)
glucocorticoids on arachidonic acid pathway
inhibits phospholipase A2 to inhibit production of arachidonic acid
this in turn decreases leukotrienes since there is no AA made, so it decreases asthma attacks
cyclooxygenase gets inhibited by
NSAIDs
GC turns on what gene to inhibit phospholipase A2
annexin 1 (lipocortin1) gets turned on to inhibit phospholipase A2
what is GILZ
glucocorticoid induced leucine zipper, GC activates GILZ to inhibit COX2, which decreases inflammatory pathway
decreases prostaglandin synthesis
corticosteroid suppression of activated inflammatory genes
interleukin 1B
granulocyte macrophage
colony stimulating factor
interleukin 6
interleukin 8
interferon y
and inducible NO synthase
NF-kB
inflammatory stimuli turns on transcription of NF-kB and as a result inflammatory genes and their respective proteins
how do GCs suppress the NF-kB target genes
GCs use GR to suppress the NF-kB target genes, competes with NF-kB
what are the potent anti-inflammatory drugs with longer plasma half life and the least mineralocorticoid action
dexamethasone and bethamethasone
decrease MR mediated side effects because 0 affinity to MR
more specific to GR which makes them high affinity binders for GR
dexamethasone has what biological half life (how long it remains in tissue)
36-54 hours
highest half life for GCs
what is dexamethasone plasma half life (time it stays in the plasma)
100-300 minutes
what is the most potent GC
dexamethasone
when is dexamethasone used
septic shock
brain edema
therapeutic effects of GC
decrease pain, stiffness, swelling, physical disability
anti-allergic
adverse effects of GCs
increase cardiovascular risk
cause cataracts (children at risk, prednisone of 10-15 mg/day or greater should receive periodic slit lamp exam), glaucoma
gastric ulcer if with NSAIDs
weight gain
increases susceptibility to infections by weakening immune system
myopathy
osteoporosis
neuro-psychiatric symptoms
specific AE of corticosteroids
cushing’s syndrome: with irregular fat distribution, moon face, purple striae, ecchymosis
fluid and electrolyte abnormalities, HTN, hypokalemic alkalosis - non specific MR effects
hyperglycemia: metabolic effects on liver and pancreas
osteoporosis due to decreased Ca absorption, inhibits osteoblast formation
myopathy: weakness of limb muscles due to proteolysis, chronic asthma of COPD pts resp muscles can be affected
immune effects: increase susceptibility to bacterial, fungal, viral infections
GC regulates hyperglycemia by
inhibiting insulin secretion from pancreas
promotes glucose production from the liver (gluconeogenesis → gluconeogenesis genes will increase)
decreases glucose uptake from skeletal muscle and adipose tissue
GC contraindication/management with DM patients
DM pt that is borderline hyperglycemic
would need to increase dose of anti-DM drug (insulin) to manage hyperglycemia in order to give GC (since GC increases hyperglycemia)
GCs possessing MR stimulating activity (non specific GCs)
hydrocortisone
prednisolone
prednisone
what is the effect of GC acting on MR
stimulates Na retention, bypassing renin-angiotensin path (RAAS) which results in HTN
how to manage HTN in pts that need to take chronic GC
spironolactone - MR antagonist to decrease HTN result
osteoporosis toxic effect of GC
diminished GI absorption of Ca both via
inhibition of vitamin D action
inhibition of intestinal calcium channel expression followed by suppression on osteoblasts
promotion of bone resorption by osteoclasts
calcium 1200mg/day and vit D 800/day supplements
osteonecrosis: cell death in bone, femoral head region common (use joint replacement)
retardation of growth and development with GC toxic effects
during fetal development stage, exposure could impair proper development
pregnant pts should not be administered GCs because it could impact kids adrenal insufficiency
withdrawal of GC therapy
underlying disease flares up
gradual tapering of daily dose or transition to alternate day regimen with gradual dose reduction
withdrawal syndrome: fever, myalgia, arthralgias, malaise
if signs of acute adrenal insufficiency (low BP, weakness, fatigue), immediate return to higher dose is warranted
rare and serious adverse effect of GCs
pseudotumor cerebri
what is pseudotumor cerebri
increased intracranial pressure with papilledema - with sudden reduction or withdrawal of GC therapy
papilledema
bulging optic disk and increased intracranial pressure
Drug interactions of GCs - do not take with
non specific GCs aggravate hypokalemia (reduced potassium) do not give with:
potassium agents (amphotericin B -anti fungal)
diuretics (loop and thiazide diuretics)
when used with anti DM meds, adjust antidiabetic drug (increase) with admin of GC and monitor blood glucose
increased risk of GI bleeding with NSAIDs
contraindication of GCs
only given for life saving conditions in DM pts
do not use as anti-inflammatory in immunocompromised or pts suffering from long term bacterial/viral/fungal infections
inhaled GCs
fluticasone
budesonide
ciclesonide
mometasone
flunisolide
inhaled GCs characteristics
higher receptor affinity for GR
gets accumulated in nasal epithelial cells
rate or frequency of cellular efflux is low - (cell efflux = cells try to kick drug out of body)
adverse effects with inhaled GCs
oropharyngeal candidiasis
osteoporosis
ophthalmic complications:
cataracts
glaucoma
dry eye disease
what synthesizes and secretes CRH
the paraventricular nucleus of the hypothalamus
what type of feedback loop does the hypothalamic pituitary axis
negative feedback loop
ACTH activates
zona fasciculata to secrete cortisol (GC)
determined by the brain
renin angiotensin activates
zona glomerulosa to release aldosterone (MC)
determined by kidney
what is the endogenously secreted glucocorticoid
cortisol
synthesized by cholesterol - pregnenolone pathway
site of synthesis is zona fasciculata
enzymes required for cortisol synthesis
steroid hydroxylases - present in zona fasciculata
metabolism of cortisol
plasma half life is 60-120
metabolism includes reduction following conjugation involving glucuronidation (soluble)
active and inactive form of cortisol
active: cortisol - mostly present in liver (liver has more 11B HSD1 makes active form)
inactive: cortisone - mostly in kidneys (11B HSD2)
11B HSD → hydroxysteroid dehydrogenase
physiological actions of cortisol
increases blood glucose by promoting gluconeogenesis
increase muscle protein catabolism to promote lipolysis from adipose
stress response
potent endogenous anti-inflammatory
immunosuppressant
disease affecting corticosteroid secretion
addison’s disease
cushing’s syndrome
cushing’s disease
addison’s disease with corticosteroid secretion
corticosteroid insufficiency due to T cell mediated autoimmune rx leading to adrenal cortex destruction
can also result due to malfunctioning HPA axis including tumors
cushing’s syndrome with corticosteroid secretion
glucocorticoid excess due to pituitary or adrenal tumors
excess chronic endogenous GC release (hyperactivation of HPA axis) or synthetic GC use/admin
cushing’s disease with corticosteroid secretion
umbrella of Cushing’s syndrome caused due to benign pituitary adenoma
treatment for addison’s disease
hydrocortisone (cortef)
prednisone
cortisone acetate
oral or injections
addisonian crisis
addison’s disease if untreated undergo infection, injury or surgery
low blood glucose, low BP due to hyponatremia and hyperkalemia
treatment of addisonian crisis
hydrocortisone along with saline and dextrose
adrenal insufficiency
addison’s disease is a type 1 or primary AI
auto antibodies form against the steroid 21 hydroxylase enzyme in 90% of cases
can be caused by viral infections or chronic use of ketoconazole, phenytoin
stabilizing meds include glucocorticoid and mineralocorticoid replacement followed by isotonic saline and 5% dextrose administrations
regulators of ACTH to treat cushing’s syndrome
pasireotide (SIGNIFOR) activates SSTR to decrease ACTH
cabergoline (DOSTINEX) activates dopamine D2 receptor agonist, which decreases ACTH release
inhibitors of cortisol synthesis to treat cushing’s syndrome
ketoconazole, metyrapone, mitotane, etomidate
target 11 beta hydroxylase, reducing cortisol formation
GR blocking agent to treat cushing’s syndrome hyperglycemia
mifepristone used to regulate GC induced hyperglycemic complications and specific conditions
general mechanisms to treat cushing’s syndrome
regulators of ACTH
inhibitors of cortisol synthesis
GR blocking agent
diagnosis of cushing’s syndrome
dex suppression test
aldosterone is regulated by
kidney
site of synthesis is zona glomerulosa
RAAS major role is to
maintain sodium homeostasis
increases re-absorption of sodium in sweat glands, salivary glands and kidneys
activated due to decrease in arterial pressure, hyponatremia and hypovolemia
aldosterone physiological functions
increased expression in Na/K ATPase and ENaC channels
maintain sodium water balance
maintain normal arterial pressure
regulation of glomerular filtration rate - GFR
metabolism of MCs
transporters: transcortin and albumin
aldosterone has low affinity to binding these proteins
high hepatic first pass metabolism leads to 75% of oral drug getting excreted
mineralcorticoids MOA
ligand binds to MR in cytosol, HSP (chaperone) detach from MR
MR-aldosterone complex undergoes nuclear translocation and bind to responsive elements
fludrocortisone
synthetic mineralocorticoid prodrug available as fludrocortisone acetate
more MR affinity even tho it is a MC and GC
what is fludrocortisone used for
addison’s disease
postural orthostatic tachycardia syndrome
adrenogenital syndrome
adverse effects of fludrocortisone excess
hypokalemia and cardiac fibrosis
conn’s syndrome
primary aldosteronism
HTN and hypokalemia
sx: HA, muscle cramps, excessive thirst
insulin resistance, DM, liver fibrosis, osteoporosis, hyperparathyroidism, depression/anxiety, disturbances of calcium and collagen metabolism
serious complications of conn’s syndrome
atrial fibrillation
MI
HF
stroke
kidney failure
primary aldosteronism occurs in the absence of
absence of renin-angiotensin activation
increased aldosterone in absence of RAAS
treatment of primary aldosteronism
spironolactone (non specific to MR), eplerenone (specific to MR)
MR receptor antagonists
2nd line is adrenalectomy (removal of adrenal gland)
spironolactone is competitive or noncompetitive
competitive antagonist at MR and lacks specificity